CYP7B1
Basic information
Region (hg38): 8:64587763-64798737
Previous symbols: [ "SPG5A" ]
Links
Phenotypes
GenCC
Source:
- hereditary spastic paraplegia 5A (Strong), mode of inheritance: AR
- congenital bile acid synthesis defect 3 (Supportive), mode of inheritance: AR
- hereditary spastic paraplegia 5A (Supportive), mode of inheritance: AR
- congenital bile acid synthesis defect 3 (Strong), mode of inheritance: AR
- hereditary spastic paraplegia 5A (Strong), mode of inheritance: AR
- congenital bile acid synthesis defect 3 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Bile acid synthesis defect, congenital, 3 | AR | Gastrointestinal | Individuals may manifest with early-onset, progressive and severe cholestatic liver disease, and early recognition may allow treatment; Liver transplanation has been described | Gastrointestinal; Neurologic | 7987300; 9802883; 18252231; 19187859; 19439420; 21567895; 21623769; 22384504 |
ClinVar
This is a list of variants' phenotypes submitted to
- Spastic paraplegia (43 variants)
- not provided (11 variants)
- Hereditary spastic paraplegia 5A (11 variants)
- Hereditary spastic paraplegia (2 variants)
- CYP7B1-related disorder (1 variants)
- Spastic ataxia (1 variants)
- Congenital bile acid synthesis defect 3 (1 variants)
- Hereditary spastic paraplegia 5A;Congenital bile acid synthesis defect 3 (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CYP7B1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 117 | 120 | ||||
missense | 174 | 190 | ||||
nonsense | 19 | 22 | ||||
start loss | 0 | |||||
frameshift | 25 | 30 | ||||
inframe indel | 7 | |||||
splice donor/acceptor (+/-2bp) | 8 | |||||
splice region | 6 | 19 | 2 | 27 | ||
non coding | 10 | 59 | 14 | 83 | ||
Total | 54 | 16 | 196 | 177 | 17 |
Highest pathogenic variant AF is 0.0000329
Variants in CYP7B1
This is a list of pathogenic ClinVar variants found in the CYP7B1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
8-64587798-C-T | CYP7B1-related disorder | Likely benign (Dec 19, 2023) | ||
8-64589816-C-T | CYP7B1-related disorder | Likely benign (Oct 11, 2023) | ||
8-64596067-A-C | Hereditary spastic paraplegia 5A | Uncertain significance (Apr 27, 2017) | ||
8-64596113-T-C | Hereditary spastic paraplegia 5A | Benign (Jan 12, 2018) | ||
8-64596240-T-A | Hereditary spastic paraplegia 5A | Uncertain significance (Jan 12, 2018) | ||
8-64596305-A-C | Hereditary spastic paraplegia 5A • Hereditary spastic paraplegia | Conflicting classifications of pathogenicity (Jan 12, 2018) | ||
8-64596531-C-T | Hereditary spastic paraplegia 5A | Uncertain significance (Jan 13, 2018) | ||
8-64596593-G-A | Hereditary spastic paraplegia 5A | Benign/Likely benign (Feb 09, 2019) | ||
8-64596631-T-C | Hereditary spastic paraplegia 5A | Uncertain significance (Apr 27, 2017) | ||
8-64596656-T-C | Spastic paraplegia | Uncertain significance (Sep 09, 2022) | ||
8-64596658-T-C | Uncertain significance (Jun 06, 2019) | |||
8-64596666-T-C | Likely benign (Sep 25, 2018) | |||
8-64596678-A-T | Spastic paraplegia | Uncertain significance (Jul 08, 2022) | ||
8-64596682-G-A | Spastic paraplegia | Uncertain significance (Feb 07, 2021) | ||
8-64596682-G-T | Spastic paraplegia | Uncertain significance (Feb 05, 2020) | ||
8-64596687-C-T | Spastic paraplegia • CYP7B1-related disorder | Conflicting classifications of pathogenicity (Dec 11, 2023) | ||
8-64596689-G-A | Spastic paraplegia | Uncertain significance (Apr 08, 2021) | ||
8-64596695-C-A | Spastic paraplegia | Uncertain significance (Jun 10, 2022) | ||
8-64596699-C-T | not specified • Spastic paraplegia | Conflicting classifications of pathogenicity (Jan 26, 2024) | ||
8-64596702-C-A | Uncertain significance (May 11, 2018) | |||
8-64596702-C-T | Spastic paraplegia | Likely benign (Sep 11, 2023) | ||
8-64596702-C-CA | Spastic paraplegia | Conflicting classifications of pathogenicity (Dec 09, 2023) | ||
8-64596706-C-T | Spastic paraplegia • Congenital bile acid synthesis defect 3 • Congenital bile acid synthesis defect 3;Hereditary spastic paraplegia 5A | Uncertain significance (Aug 09, 2022) | ||
8-64596707-G-A | Hereditary spastic paraplegia 5A • Spastic paraplegia • Hereditary spastic paraplegia • Congenital bile acid synthesis defect 3;Hereditary spastic paraplegia 5A • CYP7B1-related disorder | Pathogenic/Likely pathogenic (Jan 29, 2024) | ||
8-64596707-G-T | Spastic paraplegia | Uncertain significance (Aug 27, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CYP7B1 | protein_coding | protein_coding | ENST00000310193 | 6 | 210999 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000330 | 0.942 | 125724 | 0 | 24 | 125748 | 0.0000954 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.395 | 272 | 254 | 1.07 | 0.0000126 | 3298 |
Missense in Polyphen | 95 | 96.978 | 0.9796 | 1267 | ||
Synonymous | -1.66 | 114 | 93.5 | 1.22 | 0.00000468 | 963 |
Loss of Function | 1.80 | 12 | 20.9 | 0.575 | 0.00000123 | 258 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000246 | 0.000246 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000326 | 0.000326 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000968 | 0.0000967 |
Middle Eastern | 0.000326 | 0.000326 |
South Asian | 0.0000980 | 0.0000980 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Oxysterol 7alpha-hydroxylase that mediates formation of 7-alpha,25-dihydroxycholesterol (7-alpha,25-OHC) from 25- hydroxycholesterol (PubMed:10588945). Plays a key role in cell positioning and movement in lymphoid tissues: 7-alpha,25- dihydroxycholesterol (7-alpha,25-OHC) acts as a ligand for the G protein-coupled receptor GPR183/EBI2, a chemotactic receptor for a number of lymphoid cells (By similarity). {ECO:0000250|UniProtKB:Q60991, ECO:0000269|PubMed:10588945}.;
- Disease
- DISEASE: Congenital bile acid synthesis defect 3 (CBAS3) [MIM:613812]: A disorder resulting in severe cholestasis, cirrhosis and liver synthetic failure. Hepatic microsomal oxysterol 7-alpha-hydroxylase activity is undetectable. {ECO:0000269|PubMed:9802883}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Steroid hormone biosynthesis - Homo sapiens (human);Primary bile acid biosynthesis - Homo sapiens (human);27-Hydroxylase Deficiency;Bile Acid Biosynthesis;Congenital Bile Acid Synthesis Defect Type II;Cerebrotendinous Xanthomatosis (CTX);Zellweger Syndrome;Familial Hypercholanemia (FHCA);Congenital Bile Acid Synthesis Defect Type III;Oxidation by Cytochrome P450;Tryptophan metabolism;Metapathway biotransformation Phase I and II;Phase I - Functionalization of compounds;Metabolism of lipids;Endogenous sterols;Cytochrome P450 - arranged by substrate type;Biological oxidations;Metabolism;Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol;Synthesis of bile acids and bile salts via 27-hydroxycholesterol;Synthesis of bile acids and bile salts;Bile acid and bile salt metabolism;Metabolism of steroids;Bile acid biosynthesis
(Consensus)
Recessive Scores
- pRec
- 0.245
Intolerance Scores
- loftool
- 0.480
- rvis_EVS
- -0.36
- rvis_percentile_EVS
- 28.93
Haploinsufficiency Scores
- pHI
- 0.321
- hipred
- N
- hipred_score
- 0.207
- ghis
- 0.530
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.251
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cyp7b1
- Phenotype
- reproductive system phenotype; hematopoietic system phenotype; immune system phenotype; homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan);
Gene ontology
- Biological process
- bile acid biosynthetic process;cholesterol metabolic process;sterol metabolic process;negative regulation of intracellular estrogen receptor signaling pathway;B cell chemotaxis;cholesterol homeostasis;positive regulation of epithelial cell proliferation;oxidation-reduction process;prostate gland epithelium morphogenesis
- Cellular component
- endoplasmic reticulum membrane;organelle membrane
- Molecular function
- iron ion binding;oxysterol 7-alpha-hydroxylase activity;heme binding